TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma

被引：0

作者：

Kampel, Liyona ^{[1
,2
,4
]}

Feldstein, Sara ^{[3
,4
]}

Tsuriel, Shlomo ^{[3
,4
]}

Trejo, Leonor Leider ^{[3
,4
]}

Horowitz, Gilad ^{[2
,4
]}

Warshavsky, Anton ^{[2
,4
]}

Mansour, Jobran ^{[2
,4
]}

Hershkovitz, Dov ^{[3
,4
]}

Muhanna, Nidal ^{[1
,2
,4
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Head & Neck Canc Res Lab, Tel Aviv, Israel

[2] Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg & Maxillofacial, Tel Aviv, Israel

[3] Tel Aviv Sourasky Med Ctr, Canc Res & Pathol Inst, Tel Aviv, Israel

[4] Tal Aviv Univ, Fac Med & Hlth Sci, Tel Aviv, Israel

来源：

RADIOTHERAPY AND ONCOLOGY | 2025年 / 204卷

关键词：

TP53; Head and neck squamous cell carcinoma; Recurrence; Irradiation; PROGRESSION MODEL; CANCER; CHEMORADIOTHERAPY; CHEMOTHERAPY;

D O I：

10.1016/j.radonc.2025.110714

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Head and neck squamous cell carcinomas (HNSCC) frequently recur, and patients often develop second primary tumors. Their distinction is clinically challenging. TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.

引用

页数：5

共 28 条

[1] Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
Ang, K. Kian
Zhang, Qiang
Rosenthal, David I.
Nguyen-Tan, Phuc Felix
Sherman, Eric J.
Weber, Randal S.
Galvin, James M.
Bonner, James A.
Harris, Jonathan
El-Naggar, Adel K.
Gillison, Maura L.
Jordan, Richard C.
Konski, Andre A.
Thorstad, Wade L.
Trotti, Andy
Beitler, Jonathan J.
Garden, Adam S.
Spanos, William J.
Yom, Sue S.
Axelrod, Rita S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 2940 - +
[2] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
Bonner, James A.
Harari, Paul M.
Giralt, Jordi
Cohen, Roger B.
Jones, Christopher U.
Sur, Ranjan K.
Raben, David
Baselga, Jose
Spencer, Sharon A.
Zhu, Junming
Youssoufian, Hagop
Rowinsky, Eric K.
Ang, K. Kian
[J]. LANCET ONCOLOGY, 2010, 11 (01) : 21 - 28
[3] BOYLE JO, 1993, CANCER RES, V53, P4477
[4] Braakhuis BJM, 2004, J ORAL PATHOL MED, V33, P317
[5] Califano J, 1996, CANCER RES, V56, P2488
[6] CHUNG KY, 1993, CANCER RES, V53, P1676
[7] KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
Cohen, Ezra E. W.
Machiels, Jean-Pascal H.
Harrington, Kevin J.
Burtness, Barbara
Shin, Sang Won
Gause, Christine K.
Swift, Ann M.
Brown, Holly
Perrone, Andrea Marie
Cheng, Jonathan D.
Swaby, Ramona F.
Le Tourneau, Christophe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, Luis A.
Bardelli, Alberto
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) : 579 - +
[9] Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer
Egyud, Matthew
Sridhar, Praveen
Devaiah, Anand
Yamada, Emiko
Saunders, Stefanie
Stahlberg, Anders
Filges, Stefan
Krzyzanowski, Paul M.
Kalatskaya, Irina
Jiao, Wei
Stein, Lincoln D.
Jalisi, Scharukh
Godfrey, Tony E.
[J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (05): : 1351 - 1358
[10] Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma
Flach, Susanne
Howarth, Karen
Hackinger, Sophie
Pipinikas, Christodoulos
Ellis, Pete
McLay, Kirsten
Marsico, Giovanni
Forshew, Tim
Walz, Christoph
Reichel, Christoph A.
Gires, Olivier
Canis, Martin
Baumeister, Philipp
[J]. BRITISH JOURNAL OF CANCER, 2022, 126 (08) : 1186 - 1195

← 1 2 3 →